Drug news
NICE recommends Glivec for treatment of recurrence of GIST- Novartis
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of Glivec (imatinib) as adjuvant treatment for up to 3 years in patients with Kit-positive (CD 117) Gastro Intestinal Tumours (GIST) who are at a high risk of recurrence.This is a change of view at NICE which had originally rejected the product but changed its mind on further data being produced that showed that Glivec can delay the recurrence of GIST and sometimes increase survival.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.